CLAIMS

[Claim 1] An antihypertensive pharmaceutical composition, comprising:
Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker; and
Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker.

[Claim 2] The antihypertensive pharmaceutical composition of claim 1, wherein ~~the angiotensin II receptor blocker~~a pharmaceutically acceptable salt of Fimasartan is a Fimasartan potassium salt, hydrochloride, calcium salt, sulfate, adipate, camsylate or besylate.

[Claim 3] The antihypertensive pharmaceutical composition of claim 2, wherein ~~the angiotensin II receptor blocker~~a pharmaceutically acceptable salt of Fimasartan is a Fimasartan potassium salt.

[Claim 4] The antihypertensive pharmaceutical composition of claim 1, wherein ~~the angiotensin II receptor blocker~~a hydrate of pharmaceutically acceptable salt of Fimasartan is a Fimasartan potassium trihydrate.

[Claim 5] The antihypertensive pharmaceutical composition of claim 1, wherein ~~the calcium channel blocker~~a pharmaceutically acceptable salt of Amlodipine is an Amlodipine besylate, sulfate, camsylate, hydrochloride, potassium salt, calcium salt or adipate.

[Claim 6] The antihypertensive pharmaceutical composition of claim 5, wherein ~~the calcium channel blocker~~a pharmaceutically acceptable salt of Amlodipine is an Amlodipine besylate.

[Claim 7] The antihypertensive pharmaceutical composition of claim 1, wherein the amount of ~~the angiotensin II receptor blocker~~Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 0.5 to 240 mg, and the amount of ~~the calcium channel blocker~~Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 0.1 to 20 mg.

[Claim 8] The antihypertensive pharmaceutical composition of claim 7,
wherein the amount of ~~the angiotensin II receptor blocker~~Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 50 to 180 mg.

[Claim 9] The antihypertensive pharmaceutical composition of claim 8,
wherein the amount of ~~the angiotensin II receptor blocker~~Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 60 to 120 mg.

[Claim 10] The antihypertensive pharmaceutical composition of claim 7,

wherein the amount of ~~the calcium channel blocker~~Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 5 to 15 mg.

[Claim 11] The antihypertensive pharmaceutical composition of claim 10, wherein the amount of ~~the calcium channel blocker~~Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 5 to 10 mg.

[Claim 12] The antihypertensive pharmaceutical composition of claim 1, wherein the pharmaceutical composition is an oral dosage form.

[Claim 13] The antihypertensive pharmaceutical composition of claim 12, wherein the dosage form is a single tablet.

[Claim 14] Use of: Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker; and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker, for the preparation of a medicament for alleviation or treatment of hypertension, heart failure, coronary heart disease, ischemic heart disease, ischemic peripheral vascular disease, hypertensive renal failure, cerebral apoplexy or arteriosclerosis in a mammal.

[Claim 15] Use of: Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker; and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker,for the preparation of an antihypertensive pharmaceutical composition for treating a hypertension in a mammal.

[Claim 16] The use of claim 15, wherein the mammal is human.

[Claim 17] The use of claim 15, wherein ~~the angiotensin II receptor blocker~~a pharmaceutically acceptable salt of Fimasartan is a Fimasartan potassium salt, hydrochloride, calcium salt, sulfate, adipate, camsylate or besylate.

[Claim 18] The use of claim 17, wherein ~~the angiotensin II receptor blocker~~a pharmaceutically acceptable salt of Fimasartan is a Fimasartan potassium salt.

[Claim 19] The use of claim 15, wherein ~~the calcium channel blocker~~a pharmaceutically acceptable salt of Amlodipine is an Amlodipine besylate.

[Claim 20] The use of claim 15, wherein the amount of ~~the angiotensin II receptor blocker~~Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof comprised in the composition is in the range of 0.5 to 240 mg, and the amount of ~~the calcium channel blocker~~Amlodipine, an siomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 0.1 to 20 mg.